RE: population-level impact of the bivalent, quadrivalent, and candidate nonavalent human papillomavirus vaccines: a comparative model-based analysis

Comment

Eric J Suba et al. J Natl Cancer Inst. 2013.

. 2013 May 1;105(9):664; discussion 665-6.

doi: 10.1093/jnci/djt060. Epub 2013 Mar 15.

No abstract available

Comment in

Response.
Brisson M, Drolet M, Boily MC, Malagón T, Franco EL, Laprise J, Van de Velde N, Mayrand MH, Kliewer EV, Coutlée F. Brisson M, et al. J Natl Cancer Inst. 2013 May 1;105(9):664-5. doi: 10.1093/jnci/djt056. J Natl Cancer Inst. 2013. PMID: 23767055 No abstract available.
RE: population-level impact of the bivalent, quadrivalent, and candidate nonavalent human papillomavirus vaccines: a comparative model-based analysis.
Castle P. Castle P. J Natl Cancer Inst. 2013 Aug 21;105(16):1254. doi: 10.1093/jnci/djt187. Epub 2013 Aug 1. J Natl Cancer Inst. 2013. PMID: 23907339 No abstract available.
Response.
Suba EJ, Raab SS. Suba EJ, et al. J Natl Cancer Inst. 2013 Aug 21;105(16):1254-5. doi: 10.1093/jnci/djt188. Epub 2013 Aug 1. J Natl Cancer Inst. 2013. PMID: 23907340 No abstract available.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M. Van de Velde N, et al. J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27. J Natl Cancer Inst. 2012. PMID: 23104323